Item 5.07. Submission of Matters to a Vote of Security Holders.

At the 2022 annual meeting of stockholders (the "Annual Meeting") of Aprea Therapeutics, Inc. (the "Company") held on July 28, 2022, the proposals set forth below were submitted to the stockholders of the Company.

For more information about these proposals, please refer to the Company's proxy statement filed with the Securities and Exchange Commission on June 10, 2022. The number of votes cast for, against, or withheld, as well as abstentions and broker non-votes, if applicable, in respect to each proposal is set forth below:

Proposal 1: The Company's stockholders elected the following three directors to


             serve as Class III directors until the Company's 2025 annual meeting
             of stockholders and until their successors are duly elected and
             qualified. The votes regarding the election of the directors were as
             follows:




                                                           Broker
Director                 Votes For     Votes Withheld     Non-Votes
Class III Nominees

Oren Gilad, Ph.D. 8,230,950 712,403 4,549,748

John B. Henneman III 7,467,577 1,475,776 4,549,748

Christian S. Schade 8,062,343 881,010 4,549,748

Proposal 2: The Company's stockholders ratified the appointment of one recently


             appointed Class I director and two recently appointed Class II
             directors for the remainder of their respective terms and until their
             successors are duly elected and qualified. The votes regarding the
             ratification, on an advisory basis, of the appointment of recently
             appointed directors were as follows:



                                                                       Broker
Director                Votes For     Votes Against     Abstentions   Non-Votes
Class I Director
  Marc Duey             8,214,308        367,751          361,294         X

Class II Directors

Michael Grissinger 8,159,789 404,773 378,791 X

Rifat Pamukcu, M.D. 8,177,710 377,940 387,703 X

Proposal 3: The Company's stockholders approved the issuance, in accordance with


             Nasdaq Listing Rule 5635(a), of the Company's common stock, upon
             conversion of the Company's Series A Non-Voting Convertible Preferred
             Stock issued on May 16, 2022. The votes regarding this proposal were
             as follows:




                                                   Broker
    Votes For     Votes Against     Abstentions   Non-Votes
    7,834,449        999,916          108,988         X

Proposal 4: The Company's stockholders did not approve amendments to the


            Company's certificate of incorporation, to effect a reverse stock
            split at a ratio of 1-for-3 and 1-for-20, inclusive, with the exact
            ratio to be set within that range at the discretion of the Company's
            Board of Directors before December 31, 2022. Approval of this
            proposal required the majority vote of all outstanding shares of
            common stock. The votes regarding this proposal were as follows:




    Votes For      Votes Against     Abstentions
    11,248,289       2,180,239         64,573

Proposal 5: The Company's stockholders approved an amendment to the Company's


            2019 Equity Incentive Plan to increase the number of shares of the
            Company's common stock authorized for issuance by 2,000,000 shares.
            The votes regarding this proposal were as follows:




                                                        Broker
    Votes For     Votes Against     Votes Abstaining   Non-Votes
    6,694,237       2,198,677            50,439            X

Proposal 6: The Company's stockholders ratified the appointment of Ernst & Young


            LLP as the Company's independent registered public accounting firm
            for the fiscal year ending December 31, 2022. The votes regarding
            this ratification were as follows:




    Votes For      Votes Against     Abstentions
    12,748,782        537,487          206,832

© Edgar Online, source Glimpses